Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Trends Cardiovasc Med. 2012 Aug 29;23(1):1–4. doi: 10.1016/j.tcm.2012.08.002

Figure 1.

Figure 1

FoxC1 regulates the precisely controlled balance between pro-angiogenic pathways (e.g., MMP-mediated ECM degradation and release of VEGF from the ECM, which increases VEGF bioavailability) and anti-angiogenic pathways (e.g., sVEGFR-1-mediated VEGF sequestration) in the cornea [This figure is adapted from ( Seo et al., 2012)].